Pharmacies launched another attack on the judge overseeing opioid multidistrict litigation, telling the Sixth Circuit on Friday that he has "repeatedly disregarded" federal court rules and should be ordered to follow them.
In our latest roundup of deal-makers on the move, Sidley Austin snagged a private equity pro from Linklaters for its Singapore office, Baker Botts bolstered its media and telecommunications practice and Hogan Lovells added a veteran capital markets practitioner in London.
A ruling by Delaware Vice Chancellor J. Travis Laster has recharged stockholder rights of access to company books and records, beating down AmerisourceBergen Corp.'s efforts to stop an investor probe of opioid-control oversight failures and potentially shoring up cases the plaintiffs bar considered to be at risk.
Four companies went public Friday after raising $373 million combined in initial public offerings, marking the first four IPOs of 2020 and providing fresh capital for three Chinese issuers plus a U.S. mortgage lender.
Actor Chuck Norris and his wife abandoned their lawsuit in San Francisco County Court alleging that drugs injected into her system during an MRI left her with a lingering painful condition, according to a press release from Bracco Diagnostics Inc., one of the several drugmakers named in the suit.
A New Jersey state appeals court refused to bring back two scrapped expert witnesses for Accutane users who claim the Hoffmann-La Roche Ltd. drug caused them to develop ulcerative colitis, ruling that state Supreme Court precedent in related Accutane litigation justified keeping their testimony out of the case.
A Philadelphia County judge agreed Friday to cut an $8 billion punitive damages verdict against a Johnson & Johnson subsidiary to $6.8 million in a landmark case over side effects associated with the antipsychotic drug Risperdal.
Merck & Co.'s Idenix subsidiary urged the full Federal Circuit on Wednesday to reconsider a decision that wiped out a $2.5 billion verdict in a patent dispute with Gilead Sciences Inc., saying the ruling "threatens disaster for innovation."
A Michigan medical marijuana patient can't force the state to ease a supply shortage by tapping unregulated cannabis growers after a federal court ruled it was barred from meddling with a state agency's decisions.
The preliminary trade agreement signed by the U.S. and China this week should aid the branded pharmaceutical industry by creating a system to resolve patent disputes over generic drugs before they enter the market and a way to extend the life of drug patents, attorneys say.
The Third Circuit on Thursday refused to revive a former Pennsylvania industrial plant employee's suit claiming he was wrongly fired for complaining about not getting overtime pay, backing a district court finding that the suit was a bid to end-run around an unfavorable decision in another case.
Two former analysts for Outcome Health LLC pled guilty in Illinois federal court Thursday to charges that they participated in a criminal conspiracy involving a multi-pronged fraud that misrepresented the company’s health care advertising abilities and resources to its clients.
The U.S. Department of Justice's Antitrust Division signed off Wednesday on the American Optometric Association's plans to expand its group purchasing abilities to include lenses and other optometric products, saying that adequate safeguards have been put in place against anti-competitive harm.
A Ninth Circuit panel on Thursday rejected an appeal by users of the antidepressant Cymbalta who claimed maker Eli Lilly & Co. hid the risks of withdrawal from the drug, saying they knew they might be ending the case when they initially dropped their claims.
A Kentucky federal judge on Thursday tossed a vaping trade organization’s bid to postpone a court-mandated deadline for the U.S. Food and Drug Administration to begin enforcement action on e-cigarettes, finding the group had failed to show why the agency should be accountable for a judge’s decision.
The Sixth Circuit on Thursday vacated $655,689 in attorney fees that Cavitch Familo & Durkin Co. LPA and three of its attorneys were ordered to pay for discovery abuses in a dispute between two medical device companies, as the lawyers weren't given proper notice.
Gilead Sciences Inc., already facing political pressure and lawsuits over alleged anti-competitive behavior, was hit Wednesday with a proposed class action accusing the pharmaceutical giant of conspiring with other drugmakers to block the use of generics in HIV treatment regimens.
Albertsons is considering an IPO that could value the U.S. grocery giant at about $19 billion, educational publishing company Springer Nature could be valued at as much as €8 billion in an IPO of its own, and DuPont is weighing options for its electronics business, including a potential sale. Here, Law360 breaks down these and other deal rumors from the past week that you need to be aware of.
The Federal Circuit’s decision to uphold a $70 million infringement verdict against Hospira Inc. tied to its biosimilar version of Amgen Inc.'s Epogen "calls into question the continuing viability" of a safe harbor for drug development and approval, Hospira has told the full court.
Private equity firm Frazier Healthcare Partners said Thursday it has finalized its latest investment vehicle after raising more than $617 million from limited partners, with plans to invest in life sciences companies that are focused on the development and commercialization of novel medical treatments.
Brown Rudnick LLP is hitting back against a suit that claims the firm botched a $300 million clawback claim against the bankrupt Lyondell Chemical Co., calling the malpractice allegations little more than "Monday morning quarterbacking" and a ham-fisted attempt to avoid paying fees.
Bankrupt drugmaker Insys Therapeutics Inc. secured confirmation in Delaware on Thursday for a Chapter 11 liquidation and recovery trust that could initially make $160 million available for victims of an opioid epidemic whose potential claims could climb into the billions.
The Senate approved President Donald Trump's updated North American trade pact in a bipartisan 89-10 vote Thursday, more than a year after negotiations with Mexico and Canada concluded.
Liberty Mutual on Wednesday urged the Third Circuit to uphold the dismissal of a mail-order pharmacy's putative class action accusing the insurer of refusing to cover topical pain-relief creams as an alternative to more abuse-prone opioid pills.
A California federal judge overseeing Illumina’s patent infringement suit against China-based BGI Genomics over DNA sequencing technology gave a mixed response to BGI's counterclaims at a hearing Wednesday, saying BGI's induced infringement claim had factual support while its inequitable conduct claim didn't.
The U.S. Department of Health and Human Services accused Gilead Sciences Inc. on Wednesday of infringing four agency patents covering the use of HIV treatment medication to prevent infection, escalating a fight that has been brewing for months.
The U.S. Department of Health and Human Services' outline for allowing states to import drugs from Canada raises questions about the U.S. Food and Drug Administration's authority to implement the rule and may be an attempt to deflect blame for high drug prices to manufacturers, say attorneys at King & Spalding.
By becoming familiar with the most common problems raised in class actions against CBD products, cannabis suppliers and manufacturers can reduce risks associated with marketing, labeling and promoting their products, say Mark Goodman and Barry Thompson of Baker McKenzie.
During the last 10 years, the need to embrace change was fundamental for law firms, and that change affected associates in many ways — most, but not all, for the better, says Brad Kaufman, co-president of Greenberg Traurig.
The U.S. Department of the Treasury’s final rules implementing the Foreign Investment Risk Review Modernization Act complete the revamp of the Committee on Foreign Investment in the United States, which will be more complex and better resourced to address evolving national security risks that arise in the context of foreign investments, say attorneys at Akin Gump.
A flurry of year-end activity, including three petitions before the U.S. Supreme Court and a spate of proposed legislation, requires a recap on the current status of the debate over the Federal Trade Commission's Section 13(b) authority to obtain permanent injunctions and restitution, say John Villafranco and Khoury DiPrima of Kelley Drye.
The Second Circuit’s recent decision in U.S. v. Blaszczak potentially makes it easier to prosecute insider trading cases by ruling the government doesn't need to prove an insider received any personal benefit in exchange for sharing material, nonpublic information, say attorneys at Goodwin.
Recent initiatives by Congress and federal agencies may help expand insurance coverage for, and patient access to, genetic testing technologies that would allow more accurate diagnoses of rare diseases in the U.S. health care system, says Ethan Jorgensen-Earp of Holland & Knight.
In allowing Palmiter v. Commonwealth Health Systems to proceed, a Pennsylvania state court joins a national trend to allow medical cannabis patients to proceed with unlawful termination claims based on off-site medical cannabis use, say Ruth Rauls and Matthew Smith of Saul Ewing.
While President Donald Trump’s recent executive order expands the ability of the U.S. Office of Foreign Assets Control to sanction non-U.S. entities doing business with Iran, it remains to be seen whether OFAC will pursue aggressive enforcement of its strengthened secondary sanctions authority, say attorneys at Ropes & Gray.
Last year saw a dizzying array of drug pricing actions and proposals from the White House, Congress and state governments, and this year the drug industry may face even greater pressure from groundbreaking changes to federal policy, among other developments, say Tom Bulleit and Scott Falin of Ropes & Gray.
Last year, the U.S. Department of Justice maintained aggressive enforcement efforts in the health care industry, again relying heavily on the False Claims Act, but the agency is also taking steps to guide those efforts toward fairness and consistency, say attorneys at Mintz.
With new biosimilar applications and patent infringement complaints on the horizon, 2020 may see a rebound in patent litigation under the Biologics Price Competition and Innovation Act following a decrease last year, say Joshua Whitehill and Michael Cottler of Goodwin.
With third-party litigation funding increasingly being used to finance large and prolonged multidistrict litigations, more disclosure of funding agreements may be warranted to address potential biases and distortions of control and decision-making, say attorneys at Duane Morris.
As products using cannabigerol and cannabinol — cannabis compounds that are less well-known than THC and CBD — become more popular, understanding the legal differences under existing food and drug laws is crucial for companies marketing such products, says Ian Stewart of Wilson Elser.
In their new book "Democracy and Equality: The Enduring Constitutional Vision of the Warren Court," Geoffrey Stone and David Strauss provide valuable context for U.S. Supreme Court decisions under Chief Justice Earl Warren that have profoundly affected the country, but their overly protective attitude sometimes obscures reality, says Federal Circuit Judge Timothy Dyk.